StockMarketWire.com - Respiratory diseases focused Verona Pharma said it had entered into a debt financing facility for up to $30 million with Silicon Valley Bank.

The capital provided further financial flexibility to support pre-commercialization activities for ensifentrine, a product candidate currently in Phase 3 trials.




Story provided by StockMarketWire.com